On Thursday morning, GN Hearing brought its fiscal year to a close following a troublesome financial period, as the firm published its 2020 annual report.
The coronavirus pandemic has been particularly hard on the company in 2020, since its primary target group, the elderly segment, has generally stayed away from audiologists and, consequently, refrained from buying new hearing aids.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.